These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27906893)

  • 1. An internist's approach to cancer diseases based on the model of thyroid cancer treated with tyrosine kinase inhibitors.
    Krajewska J; Jarząb B
    Pol Arch Med Wewn; 2016 Nov; 126(11):925-928. PubMed ID: 27906893
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic management of metastatic medullary thyroid carcinoma: role of new tyrosine kinase inhibitors.
    García-Martín A; López-Ibarra Lozano PJ; Triviño-Ibáñez EM; Escobar-Jiménez F
    Endocrinol Nutr; 2013 Mar; 60(3):152-3. PubMed ID: 22565118
    [No Abstract]   [Full Text] [Related]  

  • 3. Best Use of the Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer: Discussion.
    Tuttle RM; Brose MS
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 9):12-3. PubMed ID: 27168343
    [No Abstract]   [Full Text] [Related]  

  • 4. Sequencing of Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer.
    Brose MS
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 9):7-12. PubMed ID: 27168342
    [No Abstract]   [Full Text] [Related]  

  • 5. New approaches to thyroid cancer.
    Cohen EE
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):255-6. PubMed ID: 22706487
    [No Abstract]   [Full Text] [Related]  

  • 6. [New therapies in thyroid cancer].
    López Mondéjar P; Galofré JC
    Med Clin (Barc); 2016 Apr; 146(7):324-9. PubMed ID: 26723936
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeted therapies for advanced thyroid cancer.
    Puxeddu E; Romagnoli S; Dottorini ME
    Curr Opin Oncol; 2011 Jan; 23(1):13-21. PubMed ID: 21045687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer.
    Santoro M; Carlomagno F
    Nat Clin Pract Endocrinol Metab; 2006 Jan; 2(1):42-52. PubMed ID: 16932252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor tyrosine kinase inhibitors in thyroid cancer.
    Castellone MD; Carlomagno F; Salvatore G; Santoro M
    Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):1023-38. PubMed ID: 19041829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
    Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine-kinase inhibitors to treat radioiodine-refracted, metastatic, or recurred and progressive differentiated thyroid carcinoma [Review].
    Ito Y; Suzuki S; Ito K; Imai T; Okamoto T; Kitano H; Sugitani I; Sugino K; Tsutsui H; Hara H; Yoshida A; Shimizu K
    Endocr J; 2016 Jul; 63(7):597-602. PubMed ID: 27210070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring.
    Carhill AA; Cabanillas ME; Jimenez C; Waguespack SG; Habra MA; Hu M; Ying A; Vassilopoulou-Sellin R; Gagel RF; Sherman SI; Busaidy NL
    J Clin Endocrinol Metab; 2013 Jan; 98(1):31-42. PubMed ID: 23185034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors.
    Ye L; Santarpia L; Gagel RF
    Endocr Rev; 2010 Aug; 31(4):578-99. PubMed ID: 20605972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
    Lin CI; Whang EE; Lorch JH; Ruan DT
    Surgery; 2012 Dec; 152(6):1142-9. PubMed ID: 23158184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
    Antonelli A; Bocci G; Fallahi P; La Motta C; Ferrari SM; Mancusi C; Fioravanti A; Di Desidero T; Sartini S; Corti A; Piaggi S; Materazzi G; Spinelli C; Fontanini G; Danesi R; Da Settimo F; Miccoli P
    J Clin Endocrinol Metab; 2014 Apr; 99(4):E572-81. PubMed ID: 24423321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitors in pediatric malignancies.
    Skolnik JM; Adamson PC
    Cancer Invest; 2007; 25(7):606-12. PubMed ID: 17952738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical development of kinase inhibitors for the treatment of differentiated thyroid cancer.
    Ho AL; Sherman E
    Clin Adv Hematol Oncol; 2011 Jan; 9(1):32-41. PubMed ID: 21326144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumor BRAFV600E heterogeneity and kinase inhibitors in the treatment of thyroid cancer: a call for participation.
    Vitale M
    Thyroid; 2013 Apr; 23(4):517-9. PubMed ID: 23398043
    [No Abstract]   [Full Text] [Related]  

  • 19. Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors.
    Drenberg CD; Baker SD; Sparreboom A
    Clin Pharmacol Ther; 2013 Mar; 93(3):215-9. PubMed ID: 23419484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy in refractory thyroid cancer: current achievements and limitations.
    Brilli L; Pacini F
    Future Oncol; 2011 May; 7(5):657-68. PubMed ID: 21568681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.